IGLL5 Expression in Clear Cell Kidney Cancer: Potential Prognostic Biomarker?
Posted: Thursday, April 1, 2021
According to the findings presented in FEBS Open Bio, expression of the tumor microenvironment hub gene IGLL5 may correlate with tumor-infiltrating immune cells in clear cell renal cell carcinoma cases. Cheng Zhang, MD, PhD, of the First Affiliated Hospital of the Harbin Medical University, China, and colleagues determined through immunoinfiltration analyses that three types of tumor-infiltrating immune cells may be positively associated with IGLL5 expression.
“After survival analysis and evaluation of prognostic values, IGLL5 might become a potential prognostic biomarker of clear cell renal cell carcinoma,” the authors concluded. “Combined immunotherapy based on IGLL5 inhibitor and immune checkpoint inhibitors provides a new idea and needs further study.”
In this study, the authors used computational methods to calculate the proportion of immune and stromal components and the rate of tumor-infiltrating immune cells from 539 samples of clear cell renal cell carcinoma in The Cancer Genome Atlas Program database. By examining the differentially expressed genes found by protein-protein interaction network and Cox regression analysis, the authors identified IGLL5 as the one overlapping gene.
Further analysis to verify the correlation between IGLL5 expression and the tumor microenvironment showed that three types of tumor-infiltrating immune cells were correlated with IGLL5 expression (naive B cells, plasma cells, and activated CD4 memory T cells). Additionally, they found that IGLL5 expression impacted the immunologic parameters associated with the tumor microenvironment.
“Inhibition of IGLL5 aiming to reduce the infiltration of B cells in tumors may provide a new target for combined immunotherapy,” the authors added.
Disclosure: For full disclosures of the study authors, visit www.febs.com.